Title: Irish Thoracic Society Annual Scientific Meeting 2022 Abstract Book 1 – 3 December 2022, Naas, Ireland
Abstract: Background: Herpes zoster is a significant health burden that affects individuals of any age.It is more common among individuals aged ≥ 50 years, those with immunocompromised status, and those on immunosuppressant drugs.This is likely secondary to the immunosenescence associated with advancing age 2 .An increased incidence has been reported in asthmatics 1 .Methods:A retrospective review was conducted of eosinophilic asthma patients who have commenced on Mepolizumab 100 mg subcutaneously in Portiuncula University Hospital in 2021-2022.Results:22.29%(n = 2) of patients who received Mepolizumab developed Herpes Zoster after the 1st or 2nd dose of Mepolizumab.Individuals' ages ranged from 55-71 years and cases were deemed to be mild or moderate.Conclusion:GSK reports a 0%-2% incidence of Herpes Zoster across 10 phase 3 clinical trials.The rationale for the increased risk of Herpes Zoster virus in individuals receiving Mepolizumab is unknown.A population-based case-control study yielded results noting an increased incidence of Herpes Zoster in individuals with asthma 1 .The study recommended that consideration should be given to immunizing adults with asthma aged more than 50 years as a target group.Future Recommendations:Patients aged > 50 years with a known history of Asthma receiving mepolizumab are at an increased risk of Herpes Zoster.Vaccination should be considered.